ライフサイエンスコーパス: cryptococcosis

1 on virulence in a murine inhalation model of cryptococcosis.

2 nuation of virulence in two murine models of cryptococcosis.

3 impact on pathogenicity in animal models of cryptococcosis.

4 pared by using in vivo and ex vivo models of cryptococcosis.

5 for risk stratification of individuals with cryptococcosis.

6 he SREBP pathway as a therapeutic target for cryptococcosis.

7 ts virulence was reduced in a mouse model of cryptococcosis.

8 nate and adaptive pulmonary defenses against cryptococcosis.

9 n 2 (IL-2) in a murine model of disseminated cryptococcosis.

10 egral part of clinical care of patients with cryptococcosis.

11 oteins in the development and progression of cryptococcosis.

12 responsiveness during experimental pulmonary cryptococcosis.

13 ptible hosts, respectively, for experimental cryptococcosis.

14 s in immunocompetent patients with pulmonary cryptococcosis.

15 bs2-Hog1 MAPK cascade in the pathogenesis of cryptococcosis.

16 nagement of renal transplant recipients with cryptococcosis.

17 fected tissues of patients with disseminated cryptococcosis.

18 y infected mice and a patient with pulmonary cryptococcosis.

19 s that may contribute to the pathogenesis of cryptococcosis.

20 may have in resistance and susceptibility to cryptococcosis.

21 were tested in murine models of disseminated cryptococcosis.

22 n barrier (BBB) is a key unresolved issue in cryptococcosis.

23 ococcus neoformans is the etiologic agent of cryptococcosis.

24 no effect on virulence in an animal model of cryptococcosis.

25 tenuated for virulence in the mouse model of cryptococcosis.

26 h2 cells using a mouse model of experimental cryptococcosis.

27 e and were hypervirulent in animal models of cryptococcosis.

28 shown to be protective against experimental cryptococcosis.

29 frequently involved with a fatal outcome of cryptococcosis.

30 ounds, may have utility for the treatment of cryptococcosis.

31 importance of urease in the pathogenesis of cryptococcosis.

32 ion status, or the subsequent development of cryptococcosis.

33 search for alternative roles for laccase in cryptococcosis.

34 evelopment of vaccination strategies against cryptococcosis.

35 d cryptococci are critical in the outcome of cryptococcosis.

36 ent was associated with a decreased risk for cryptococcosis.

37 mice prolonged survival in a mouse model of cryptococcosis.

38 a candidate for phase I trial in humans with cryptococcosis.

39 rway towards developing a vaccine to prevent cryptococcosis.

40 have promise as therapeutic reagents against cryptococcosis.

41 routine testing of BALs for CrAg to diagnose cryptococcosis.

42 for the eventual use of MAbs in treatment of cryptococcosis.

43 nisms and is therapeutic in murine models of cryptococcosis.

44 y for the prophylaxis and treatment of human cryptococcosis.

45 r polysaccharides important for virulence in cryptococcosis.

46 occus neoformans alters the course of murine cryptococcosis.

47 l protection against development of cerebral cryptococcosis.

48 ted tissues of individuals with disseminated cryptococcosis.

49 is; 4% had invasive aspergillosis and 3% had cryptococcosis.

50 fected tissues are hallmarks of disseminated cryptococcosis.

51 ated the expression of iNOS in rat pulmonary cryptococcosis.

52 tion and the defects present in uncontrolled cryptococcosis.

53 ed risk of IRS in transplant recipients with cryptococcosis.

54 were validated in a murine model of systemic cryptococcosis.

55 thout fluconazole for primary prophylaxis of cryptococcosis.

56 lso have implications for treatment of human cryptococcosis.

57 ise in clinical fungal infections, including cryptococcosis.

58 sed intracranial pressure (ICP) is common in cryptococcosis.

59 o clinical presentation and outcome in human cryptococcosis.

60 s known regarding capsule phenotype in human cryptococcosis.

61 ts were correlated with laboratory-confirmed cryptococcosis.

62 to optimize the management of posttransplant cryptococcosis.

63 e preventive and/or treatment strategies for cryptococcosis.

64 azole, the widely used drug for treatment of cryptococcosis.

65 nes clinically available to treat or prevent cryptococcosis.

66 nts with abnormal mental status, 95% had CNS cryptococcosis.

67 a multicenter cohort of SOT recipients with cryptococcosis.

68 rbated disease in murine models of pulmonary cryptococcosis.

69 Caenorhabditis elegans and rabbit models of cryptococcosis.

70 been reported in the rat model of pulmonary cryptococcosis.

71 hese cells might contribute to resistance to cryptococcosis.

72 required for virulence in a murine model of cryptococcosis.

73 ht be at greater risk for the development of cryptococcosis.

74 s that IgM might contribute to resistance to cryptococcosis.

75 agnoses, the kappa statistic was highest for cryptococcosis (0.67) and CD4 cell count less than 200 (

76 s 5-FC is indicated for C. gattii neurologic cryptococcosis (6 weeks) and when localized to lung (2 w

77 us mycobacteriosis, 79% and 18 (15.51/0.84); cryptococcosis, 76% and 4 (5.80/1.35); and histoplasmosi

78 cellular pathogen and the causative agent of cryptococcosis, a disease that is often fatal to those w

79 Twenty-five of 92 patients had confirmed cryptococcosis; all sera (n = 56) from these patients we

80 However, cryptococcosis also occurs in individuals with apparentl

81 ry response often seen in AIDS patients with cryptococcosis and candidiasis is not secondary to subop

82 ow the same virulence in different models of cryptococcosis and equivalent levels of competition in c

83 ngal pathogen that is the causative agent of cryptococcosis and fatal meningitis in immuno-compromise

84 To determine the incidence of cryptococcosis and its risk factors among human immunode

85 lar glucuronoxylomannan (GXM) is shed during cryptococcosis and taken up by macrophages.

86 n augmenting host resistance to disseminated cryptococcosis and that IFN-gamma is essential for effic

87 n important source of MCP-1 during pulmonary cryptococcosis and that MCP-1 production is actively reg

88 Due to the increasing global risk of cryptococcosis and the emergence of drug-resistant strai

89 es (AM) comprise the initial host defense in cryptococcosis and they may arrest infection before diss

90 ts to distinguish meningeal and nonmeningeal cryptococcosis and to identify clinical characteristics

91 2 of 2 with invasive fusariosis, 1 of 1 with cryptococcosis, and 1 of 2 with zygomycosis.

92 nicilliosis marneffei, 2.9% of patients with cryptococcosis, and 1.1% of patients with aspergillosis.

93 HIV-positive individuals who did not develop cryptococcosis, and in HIV-negative individuals.

94 sent an alternative for the therapy of human cryptococcosis, and monoclonal antibody 18B7 (IgG1) is a

95 tivity, lack of growth in an animal model of cryptococcosis, and morphological defects.

96 mponents that protect mice from disseminated cryptococcosis, and this protection appears to be T-cell

97 Thus, outcome in transplant recipients with cryptococcosis appears to be influenced by the type of i

98 how that protective immune responses against cryptococcosis are associated with Th1-type cytokine pro

99 Most cases of cryptococcosis are caused by Cryptococcus neoformans var

100 Because candidiasis and cryptococcosis are common in human immunodeficiency viru

101 nd their possible role in protection against cryptococcosis are not known.

102 tive approaches to prevention and therapy of cryptococcosis are urgently needed.

103 diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis,

104 experience clinical deterioration, known as cryptococcosis-associated immune reconstitution inflamma

105 Cryptococcosis-associated immune reconstitution inflamma

106 deterioration, in part caused by paradoxical cryptococcosis-associated immune reconstitution inflamma

107 management of cirrhotic patients who develop cryptococcosis before transplantation are not fully know

108 ving consecutive patients with cirrhosis and cryptococcosis between January 2000 and March 2014.

109 val rates and occurrences of newly diagnosed cryptococcosis between patients with and without flucona

110 contributed to virulence in a mouse model of cryptococcosis but only in a mutant that also lacked the

111 infection in the murine inhalation model of cryptococcosis but still causes brain infection in a mur

112 activity is involved in the pathogenesis of cryptococcosis but that the importance may be species an

113 stmicin was efficacious in a mouse model for cryptococcosis, but it was less active than predicted fr

114 Given the increasing prevalence of cryptococcosis caused by Cryptococcus gattii (serotypes

115 We describe the first case of cryptococcosis caused by Cryptococcus neoformans var. ga

116 ental for understanding pathogenesis because cryptococcosis commonly presents as meningoencephalitis.

117 We report a case of cryptococcosis due to C. gattii which appears to have be

118 ion is often obtained to treat patients with cryptococcosis due to the complex nature of the disease,

119 ion is often obtained to treat patients with cryptococcosis due to the complex nature of the disease,

120 de, for example, management of pretransplant cryptococcosis during transplant candidacy and timing of

121 the absence of CM can represent early-stage cryptococcosis during which antifungal treatment might i

122 ents comprised 83 transplant recipients with cryptococcosis followed for a median of 2.1 and up to 5.

123 Although cryptococcosis has been associated with birds for almost

124 that patients who are at increased risk for cryptococcosis have lower serum levels of GXM-reactive I

125 solid organ transplant (SOT) recipients with cryptococcosis have not been fully defined.

126 i (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis)

127 Africa (GERMS-SA), we reviewed all cases of cryptococcosis in 2005 and 2006.

128 Cryptococcus neoformans from a case of nasal cryptococcosis in a cat.

129 assessed antifungal treatment practices for cryptococcosis in a cohort of prospectively followed org

130 f 122 solid organ transplant recipients with cryptococcosis in a multicenter study from 1999 to 2006.

131 fluence of IgM on susceptibility to systemic cryptococcosis in a murine model, we compared the surviv

132 comprised 54 renal allograft recipients with cryptococcosis in a prospective, multicenter study.

133 ssed in 111 organ transplant recipients with cryptococcosis in a prospective, multicenter, internatio

134 A striking feature of cryptococcosis in AIDS is high serum levels of the major

135 CrAg LFA) was evaluated for the diagnosis of cryptococcosis in HIV-negative patients.

136 causes serious infections in AIDS patients, cryptococcosis in immunologically immature infants, as i

137 stances; potential for donor transmission of cryptococcosis in light of recent fatal transmissions; a

138 chloroquine was therapeutic in experimental cryptococcosis in outbred and severe combined immunodefi

139 Cryptococcosis in patients with cirrhosis has grave prog

140 ospective cohort of 147 consecutive cases of cryptococcosis in patients without HIV.

141 ospective cohort of 147 consecutive cases of cryptococcosis in patients without HIV.

142 aspergillosis, zygomycosis, fusariosis, and cryptococcosis in SOT recipients intolerant of or failin

143 ese results indicate that serial episodes of cryptococcosis in South Africa are frequently associated

144 cribe persons with AIDS currently developing cryptococcosis in the era of highly active antiretrovira

145 t a potential role for subclinical pulmonary cryptococcosis in the pathogenesis of asthma.

146 Progression of pulmonary cryptococcosis in the presence of nonprotective T(2) imm

147 There is an ongoing outbreak of cryptococcosis in the western United States and Canada.

148 apeutic approach and duration of therapy for cryptococcosis in transplant recipients.

149 ans causes severe, and often fatal, disease (cryptococcosis) in immunocompromised patients, particula

150 rus (HIV)-positive individuals who developed cryptococcosis, in matched samples from HIV-positive ind

151 In rats with experimental pulmonary cryptococcosis, increased lung levels of TGF were presen

152 host defense in a murine model of pulmonary cryptococcosis induced by intratracheal inoculation of C

153 tream of mice to simulate the antigenemia in cryptococcosis, inhibits PMN accumulation at the site of

154 Cryptococcosis is a disease resulting from the inhalatio

155 Cryptococcosis is a fungal disease caused by Cryptococcu

156 Cryptococcosis is a leading cause of death among individ

157 Cryptococcosis is a significant opportunistic mycoses in

158 Disseminated cryptococcosis is accompanied by cryptococcal polysaccha

159 Compared to the incidence in adults, cryptococcosis is inexplicably rare among children, even

160 iciency syndrome (AIDS)-related disseminated cryptococcosis is possible in patients receiving highly

161 ce to Cryptococcus neoformans disease (i.e., cryptococcosis) is unknown.

162 ormans, the predominant etiological agent of cryptococcosis, is an opportunistic fungal pathogen that

163 ptococcus neoformans, the causative agent of cryptococcosis, is an opportunistic fungal pathogen that

164 The disease, cryptococcosis, is mostly acquired by inhalation and can

165 In murine models of cryptococcosis, MAb 2H1 administration prolongs survival

166 the rabbit and the mouse models of invasive cryptococcosis, man1 was shown to be severely impaired i

167 eurological damage in HIV- subjects with CNS cryptococcosis may help gauge disease severity and guide

168 resulted in attenuated virulence in a mouse cryptococcosis model that was restored by complementatio

169 d this immunotherapy using a direct cerebral cryptococcosis model to study direct effects in the brai

170 on, abnormal mental status, time to onset of cryptococcosis more than 24 months posttransplantation (

171 spergillosis (n = 20), candidiasis (n = 10), cryptococcosis (n = 9), and histoplasmosis (n = 11) reve

172 constitution syndrome (IRS) in the course of Cryptococcosis neoformans infection in renal transplant

173 gnificant predictor of future development of cryptococcosis (odds ratio, 14; P = .02).

174 ry B cells in banked samples obtained before cryptococcosis onset from 31 participants in the Multice

175 report we examine outcomes of patients with cryptococcosis or dimorphic fungal infections treated wi

176 l fluid (CSF) samples from 44 and 33 non-HIV cryptococcosis patients, respectively.

177 The annual incidence of cryptococcosis per 1000 among persons living with AIDS r

178 IV-infected persons, the annual incidence of cryptococcosis ranged from 0.2 to 0.9/100,000.

179 rity of the organ transplant recipients with cryptococcosis receive maintenance antifungal therapy fo

180 icantly associated with an increased risk of cryptococcosis; receiving fluconazole within 3 months be

181 Cryptococcosis remains a significant cause of morbidity

182 o antifungal agents used in the treatment of cryptococcosis remains uncommon among isolates of C. neo

183 Although resistance to cryptococcosis requires intact T-cell immunity, a possib

184 her studies of the role of B cells in murine cryptococcosis, SCID mice were reconstituted with lympho

185 s have a central role in the pathogenesis of cryptococcosis since they are an important line of defen

186 might confer enhanced resistance to systemic cryptococcosis, stemming in part from the antifungal act

187 Fifty sera from 67 patients without cryptococcosis tested negative in both assays.

188 selectin in serum samples from subjects with cryptococcosis than in those from uninfected subjects.

189 Gal-3-deficient mice are more susceptible to cryptococcosis than WT animals, as demonstrated by the h

190 ar macrophages, have provided a new model of cryptococcosis that could have broad implications for hu

191 ntent imaging method in a zebrafish model of cryptococcosis that permits the detailed analysis of mac

192 IV-infected individuals who had a history of cryptococcosis (the HIV+CN+ group) with levels in 30 hum

193 had HIV infection and subsequently developed cryptococcosis (the HIV+CN+ group), 8 had HIV infection

194 HIV)-infected subjects who had no history of cryptococcosis (the HIV+CN- group) and 20 HIV-uninfected

195 up), 8 had HIV infection and did not develop cryptococcosis (the HIV+CN- group), and 15 did not have

196 IV-uninfected subjects who had no history of cryptococcosis (the HIV- group) (cohort 1).

197 d not have HIV infection and did not develop cryptococcosis (the HIV- group) (cohort 2).

198 d the intravenous infection models of murine cryptococcosis, the congenic a and alpha strains display

199 In two mouse models of cryptococcosis, the tsa1 Delta mutant is significantly l

200 ) independently identified patients with CNS cryptococcosis; the risk of CNS disease was 14% if none,

201 both BALB/c and C.B-17 mice clear pulmonary cryptococcosis through T cell-mediated mechanisms, Ig H

202 ikelihood of phenotypic switching in chronic cryptococcosis; thus this mechanism may account for the

203 We used the murine intranasal model of cryptococcosis to compare the lethality of clinical and

204 be colonised by cryptococci and can transmit cryptococcosis to humans via inhalation of inoculated bi

205 del, we explored the potential for pulmonary cryptococcosis to modify allergic responses and airway r

206 eal candidiasis, CMV disease, extrapulmonary cryptococcosis, toxoplasmic encephalitis, tuberculosis,

207 Patients with disseminated cryptococcosis typically have measurable levels of crypt

208 Criterion for diagnosis of pulmonary cryptococcosis was (a) the histopathologic presence of t

209 Central nervous system cryptococcosis was documented in 61 patients.

210 Graft rejection after cryptococcosis was observed in 15.4% (2/13) of the patie

211 The risk of disseminated cryptococcosis was significantly higher for liver transp

212 The course of pulmonary cryptococcosis was studied in more detail in the CD14(-/

213 sitive CrAg LFA results in patients for whom cryptococcosis was ultimately excluded.

214 s age-related difference in the incidence of cryptococcosis, we investigated isolates of C. neoforman

215 passive immunization for treatment of murine cryptococcosis, we noted the occurrence of an acute, let

216 mmunodeficiency virus-infected patients with cryptococcosis were analyzed to determine whether persis

217 SOT recipients with cryptococcosis were identified and followed for 12 month

218 while 17/18 urine samples from patients with cryptococcosis were positive by the LFA.

219 nt patients with clinically proved pulmonary cryptococcosis were retrospectively reviewed by four rev

220 les from 92 patients with known or suspected cryptococcosis were tested by LA and LFA, and titres wer

221 to reduce AIDS-attributable mortality due to cryptococcosis which remains 20-25% in sub-Saharan Afric

222 an encapsulated fungal pathogen that causes cryptococcosis, which is a major opportunistic infection

223 Cryptococcus neoformans are causal agents of cryptococcosis, which manifests as pneumonia and meningi

224 rejection in 66% (2/3) of the patients with cryptococcosis who developed IRS compared to 5.9% (3/51)

225 in 6 patients with a history of disseminated cryptococcosis who had received > or =12 months of antif

226 e strongly considered in SOT recipients with cryptococcosis who have late-onset disease, fungemia, or

227 Of 129 (88%) of 146 SOT recipients with cryptococcosis who underwent CSF analysis, 80 (62%) had

228 ition (n = 11) or began therapy for possible cryptococcosis without improvement (n = 2), leading to a